Show simple item record

dc.contributor.advisorPalma, Oscar 
dc.creatorPadrón Barrios, Carlos Andrés
dc.descriptionEl uso masivo de antibióticos como un arma frente a las enfermedades causadas por patógenos ha causado una crisis mundial de resistencia antimicrobial, con consecuencias que solo queden ser abordadas en un sentido global debido a su extensión transnacional. El régimen sanitario internacional ha hecho esfuerzos significativos para enfrentar la situación a través de un marco que puede ser comprendido como un proceso de securitización, identificando la resistencia como una amenaza a la seguridad internacional bajo el ámbito de la Seguridad Humana. Aun así, las tendencias crecientes en resistencia antimicrobial, así como el lento avance de en el desarrollo de nuevos tipos de antibióticos demuestran un evidente fallo de estos esfuerzos. Este texto pretende exponer la desconexión existente entre los esfuerzos hechos por el régimen sanitario y los resultados preocupantes en cuanto al preocupante patrón de resistencia. Con este objetivo, se argumentará que el proceso internacional de securitización ha fallado en el intento de resolver la amenaza de la resistencia antimicrobial como un problema de seguridad debido a la ausencia de métodos de implementación basados en la administración de riesgos.
dc.description.abstractThe widespread use of antibiotics as a weapon against microbial-driven disease has led to a world crisis of antimicrobial resistance, with consequences that could only be addressed in a global fashion due to its transnational extent. The international public health regime has made significant efforts to address the situation through a scheme that could be analyzed as a securitization process, identifying such resistance as a threat to international security under the scope of Human Security. Nevertheless, the recent increasing trends in pathogen resistance, as well as a slow pace in the development of new antibiotics prove these efforts to be failing. This paper intends to expose the disconnection between the efforts made by the regime and the worrying results in antimicrobial resistance trends. In order to do this, the text argues that the international process of securitization has failed to address the threat of Anti-Microbial Resistance as a security issue due to its absence of an appropriate risk management approach to implementation.
dc.sourceinstname:Universidad del Rosario
dc.sourcereponame:Repositorio Institucional EdocUR
dc.subjectResistencia antimicrobial
dc.subjectAdministración de riesgos
dc.subjectRégimen sanitario
dc.subjectSeguridad Humana
dc.subject.ddcFarmacología & terapéutica 
dc.subject.lembAgentes antiinfecciosos
dc.titleSecuritization and Risk Management: The Global Fight Against Antimicrobial Resistance
dc.publisherUniversidad del Rosario
dc.publisher.programRelaciones Internacionales
dc.publisher.departmentFacultad de Relaciones Internacionales
dc.subject.keywordAntimicrobial resistance
dc.subject.keywordRisk management
dc.subject.keywordPublic health regime
dc.subject.keywordHuman Security
dc.type.spaTrabajo de grado
dc.rights.accesoAbierto (Texto Completo)
dc.source.bibliographicCitationBuilder, M. (2014). Antimicrobial Resistance as an Emerging Threat to National Security. Washington, DC: Atlantic Council: Brent Scowcroft Center on International Security.
dc.source.bibliographicCitationBuzan, B. (1991). New patterns of global security in the twenty-first century. International Affairs, 67(3), 431-451.
dc.source.bibliographicCitationBuzan, B., Wæver, O., & De Wilde, J. (1998). Security: A New Framework for Analysis. Boulder: Lynne Rienner.
dc.source.bibliographicCitationCallaway, E. (2015, July 31). Succesful Ebola vaccine provides 100% protection in trial. Nature.
dc.source.bibliographicCitationDubourg, G., Abat, C., & Raoult, D. (2017). Why new antibiotics are not obviously useful now. International Journal of Antimicrobial Agents, 549-553.
dc.source.bibliographicCitationDuerden, B., Fry, C., Johnson, A. P., & Wilcox, M. H. (2015). The Control of Methicillin-Resistant Staphylococcus aureus Blood Stream Infections in England. Open Forum Infectious Diseases.
dc.source.bibliographicCitationFerri, M., Ranucci, E., Romagnoli, P., & Giaccone, V. (2017). Antimicrobial resistance: Aglobal emerging threat to public health systems. Critical Reviews in Food, Science and Nutrition, 2857-2876.
dc.source.bibliographicCitationFidler, P. D., & Gostin, O. L. (2006). The New International Health Regulations: An Historic Development for International Law and Public Health. Articles by Maurer Faculty, 85-94.
dc.source.bibliographicCitationFifty-first World Health Assembly. (1998). Emerging and other communicable diseases: antimicrobial resistance. WHA51.17. Geneva: World Health Organization.
dc.source.bibliographicCitationFleming, A. (1945, December 11). Penicillin. Nobel Lecture.
dc.source.bibliographicCitationHigh-level Panel on Threats, Challenges and Change. (2004). A more secure world: Our shared responsibility. New York: United Nations.
dc.source.bibliographicCitationInstitute of Medicine of the National Academies. (2010). Antibiotic Resistance: Implications for Global Health and Novel Intervention Strategies. Washington, DC: National Academy of Sciences.
dc.source.bibliographicCitationKlevens RM, E. J. (2007). Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Public Health Rep., 160-166.
dc.source.bibliographicCitationKrasner, S. D. (1982). Structural causes and regime consequences: regimes as intervening variables. International Organization, 185-205.
dc.source.bibliographicCitationLo Yuk-ping, C., & Thomas, N. (2010). How is health a security issue? Politics, responses and issues. Health and Policy Planning, 447-453.
dc.source.bibliographicCitationMehta, D., & Sharma, A. K. (2016). Cephalosporins: A Review on Imperative Class of Antibiotics. Molecular Pharmacology, 1.
dc.source.bibliographicCitationMoss, F. (1995). Risk management and quality of care. Quality in Health Care, 102-107.
dc.source.bibliographicCitationPiddock, L. J. (2015). Teixobactin, the first of a new class of antibiotics discovered by iChip technology? Journal of Antimicrobial Chemotherapy, 2679-2680.
dc.source.bibliographicCitationRoca, I., Akova, M., Baquero, F., Carlet, J., Cavaleri, M., Coenen, S., . . . Vila, J. (2015). The global threat of antimicrobial resistance: science for intervention. New Microbes and New Infections, 6(C).
dc.source.bibliographicCitationRossolini, G. M., Arena, F., Pecile, P., & Pollini, S. (2014). Update on the resistance crisis. Current Opinion in Pharmacology, 56-60.
dc.source.bibliographicCitationSlee, A. M., Wuonola, M. A., McRipley, R. J., Zacjac, I., Zawada, M. J., Bartholomew, P. T., . . . Forbes, M. (1987). Oxazolidinones, a New Class of Synthetic Antibacterial Agents: In Vitro and In Vivo Activities of DuP 105 and DuP 721. AntimicrobialAgents and Chemotherapy, 1791-1797.
dc.source.bibliographicCitationSmolinski, M. S., Hamburg, M. A., & Lederberg, J. (2003). Microbial Threats to Health: Emergence, Detection, and Response. Washington D.C.: National Academies Press.
dc.source.bibliographicCitationTaylor, J., Hafner, M., Yerushalmi, E., Smith, R., Bellasio, J., Vardavas, R., . . . Rubin, J. (2014). Estimating the Economic Costs of Antimicrobial Resistance. Retrieved from RAND Europe:
dc.source.bibliographicCitationThucydides. (trans. 1974). History of the Peloponnesian War. Penguin UK.
dc.source.bibliographicCitationUnemo, M. (2015, August 21). Current and future antimicrobial treatment of gonorrhoea - the rapidly evolving Neisseria gonorrhoeae continues to challenge. BMC Infectious Diseases.
dc.source.bibliographicCitationUnited Nations Development Programme. (1994). Human Development Report . New York: Oxford University Press.
dc.source.bibliographicCitationVentola, C. L. (2015, April). The Antibiotic Resistance Crisis. Pharmacy and Therapeutics, 277-283.
dc.source.bibliographicCitationWeir, L. (2015). Inventing Global Health Security, 1994-2005. In S. Rushton, & J. Youde, Routledge Handbook of Global Health Security (pp. 18-31). London and New York: Routledge, Taylor & Francis Group.
dc.source.bibliographicCitationWHO. (2015). Global Action Plan on Antimicrobial Resistance. Geneva: World Health Organization.
dc.source.bibliographicCitationWHO. (2017). World Health Organization. Retrieved from Antimicrobial Resistance:
dc.source.bibliographicCitationWi, T., Lahra, M. M., Ndowa, F., Manju, B., Dillon, J.-A. R., Ramon-Pardo, P., . . . Unemo, M. (2017). Antimicrobial resistance in Neisseria gonorrhoeae: Global surveillance and a call for international collaborative action. PLoS Med.
dc.source.bibliographicCitationWishnick, E. (2010). Dilemmas of securitization and health risk management in the People's Republic of China: the cases of SARS and avian influenza. Health Policy and Planning, 454-466.
dc.source.bibliographicCitationWorld Economic Forum. (2013). The Dangers of Hubris on Human Health. Retrieved from Global Risks 2013 Eighth Edition:
dc.source.bibliographicCitationWorld Health Organizacion. (2017). Global priority list of intibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. WHO. Retrieved from
dc.source.bibliographicCitationWorld Health Organization. (2005). International Health Regulations, Third Edition. Geneva: WHO.
dc.source.bibliographicCitationWorld Health Organization. (2011). Policy Package to Combat Antimicrobial Resistance. Retrieved from World Health Day 2011:
dc.source.bibliographicCitationWorld Health Organization. (2016). Sexually transmitted infections (STIs). WHO. Retrieved from
dc.source.bibliographicCitationYoude, J., & Rushton, S. (2015). Introduction. In J. Youde, & S. Rushton, Routledge Handbook of Global Health Security (pp. 1-3). London and New York: Routledge, Taylor and Francis Group.
dc.rights.ccAtribución-NoComercial-SinDerivadas 2.5 Colombia
dc.rights.licenciaEL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe. EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización. -------------------------------------- POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos.

Files in this item


This item appears in the following Collection(s)

Show simple item record
Except where otherwise noted, this item's license is described as